Marker Therapeutics (MRKR) Q2 2026 earnings summary

Executive summary

• Clinical-stage immuno-oncology company focused on T cell-based therapies for hematological malignancies and solid tumors, advancing MAR-T cell technology for multiple indications including lymphoma and pancreatic cancer.

• Pipeline includes autologous and off-the-shelf MAR-T cell products, with ongoing clinical trials and recent grant funding to support development.

• Manufacturing partnerships and technology transfer agreements in place to support clinical and future commercial production.

Financial highlights

• Cash, cash equivalents, and restricted cash totaled $11.9 million as of June 30, 2026, down from $17.0 million at December 31, 2025.

• Operating expenses for the three and six months ended June 30, 2026 were $2.6 million and $6.7 million, respectively, down from $5.1 million and $10.1 million in the prior year periods.

• Net loss for the three and six months ended June 30, 2026 was $1.8 million and $5.0 million, respectively, compared to $4.0 million and $8.5 million in the prior year periods.

• Grant income for the six months ended June 30, 2026 was $1.4 million, up from $1.2 million in the prior year period.

• No revenues from product sales; operations funded primarily by equity, warrants, and grants.

Outlook and guidance

• Current cash position expected to fund operations into the second quarter of 2027, assuming no additional grant funds are received.

• Management is considering raising additional capital and applying for further grant funding to extend the operating runway.

• Continued investment in research and development and clinical trials anticipated to result in ongoing net losses for the foreseeable future.